Trial Profile
Efficacy, Safety and Long-Term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 04 Jun 2009 New trial record.